Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)
This NIH program supports preclinical discovery and development of biologic-based therapies for nervous system disorders, from lead optimization through Phase I clinical testing. Eligible applicant…
- Deadline
- Aug 18, 2027
- Posted
- Oct 1, 2024
- Award amount
- Amount not specified
- Focus areas
- EducationEnvironmentHealth
Don’t miss this deadline
We’ll email you before Aug 18, 2027 so you have time to apply.
In plain English
This NIH program supports preclinical discovery and development of biologic-based therapies for nervous system disorders, from lead optimization through Phase I clinical testing. Eligible applicants are research organizations such as universities, colleges, government and tribal agencies, faith- or community-based organizations, and (for this announcement) foreign organizations; it is geared toward established research teams, not individuals or general nonprofits. Award amounts are not specified. Applicants should be prepared for a complex, multi-phase research undertaking with NIH-funded consultants and contract research organizations.
AI-generated summary to help you decide quickly — verify the official eligibility rules before applying.
Who can apply
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
About this grant
The Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics) provides support for biologic-based therapeutic discovery and development, from lead optimization through phase I clinical testing. This Funding Opportunity Announcement (FOA) supports preclinical discovery and development of potential therapeutic Biotechnology Products and Biologics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies). Applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in manufacturing, scaling, pharmacokinetics, toxicology, and Phase I clinical testing. BPN-Biologics awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN-Biologics contractors (and thereby control the patent prosecution and licensing negotiations) for biotherapeutic candidates developed in this program.
Let AI draft your application
Your first draft is free: a narrative and budget outline tailored to this grant, emailed to you. Drafts are written in a nightly batch, so it arrives by email later — not instantly on this page.
Application Kit — $49 one-time
Winner intelligence + a first-draft narrative grounded in applications that actually won. One payment, no subscription.
Get the Application Kit →Related grants
Other open grants funding Education, Environment and Health — soonest deadline first.
Substance Use/Substance Use Disorder Dissertation Research Award (R36 Clinical Trials Not Allowed)
National Institutes of Health · Amount varies · Due in 17 days
Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2024, 2025, and 2026 (P50 Clinical Trial Required)
National Institutes of Health · Amount varies · Due Sep 25, 2026
National Cancer Institute Youth Enjoy Science Research Education Program (R25 Clinical Trial Not Allowed)
National Institutes of Health · Up to $400K · Due Sep 28, 2026
BRAIN Initiative: Next-Generation Devices for Recording and Modulation in the Human Central Nervous System (UG3/UH3 Clinical Trial Optional)
National Institutes of Health · Amount varies · Due Sep 28, 2026
BRAIN Initiative: Clinical Studies to Advance Next-Generation Devices for Recording and Modulation in the Human Central Nervous System (UH3 Clinical Trial Optional)
National Institutes of Health · Amount varies · Due Sep 28, 2026
Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed)
National Institutes of Health · Amount varies · Due in 17 days
Also listed under National Institutes of Health, Education Grants and Environmental Grants.
Source: public records via Grants.gov. UseGrants is an independent aggregator, not affiliated with any funding agency. Always confirm details on the official listing before applying.